BioXcel Therapeutics Q2 net loss narrows to USD 27.4 million; revenue rises 51.67% to USD 182,000
BTAI•Expenses and balance sheet
Research and development expense fell 58.69% to USD 6.12 million, reflecting completion of the SERENITY At-Home Phase 3 trial.
Selling, general and administrative expense increased 27.17% to USD 14.38 million on higher legal and consulting fees.
Cash, cash equivalents and restricted cash totaled USD 13.8 million, with USD 107.15 million of principal debt outstanding under the Credit Agreement.
Second-quarter and six-month results
BioXcel Therapeutics posted a net loss of USD 27.4 million for the six months ended June 30, 2026.
Revenue rose 52.08% to USD 388,000 over the same period.
